Protocol Ledger

NCT05221320 · Phase II · TERMINATED

Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies

Interventional Phase II clinical trial protocol NCT05221320 sponsored by BioMed Valley Discoveries in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-05-26 Enrollment: 47 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05221320
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)47 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05221320
Protocol FieldVerified Registry Value
NCT IdentifierNCT05221320
Consolidated Lead SponsorBioMed Valley Discoveries
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment47 participants (ACTUAL)
Registered Start Date2022-05-26
WhyStopped ClassificationInsufficient / Slow Accrual

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI